ArticleDiscover oncology2026
A bibliometric analysis of trends and hotspots in Oncostatin M.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOncostatin M (OSM) belongs to the interleukin-6 (IL-6) cytokine family, with diverse physiological effects impacting various diseases. Despite substantial research on OSM, a systematic overview of the field’s current landscape and evolving trends remains limited. This study aims to objectively analyze the research status and trends in OSM using bibliometric applications, providing insights into the field’s evolution and future directions.
methodPublications were retrieved from the Web of Science Core Collection database (WOSCC) for the period from January 1, 1999, to February 3, 2026. VOSviewer, CiteSpace, and the R package “bibliometrix” were used to generate a visual knowledge map and conduct bibliometric analysis.
resultOur search yielded 811 publications (773 articles and 38 reviews). These involved 4578 authors from 995 institutions across 51 countries/regions. China (159 publications, 0.03 centrality) and the United States (157 publications, 0.55 centrality) are the most pivotal countries. INSERM contributed the most publications (n = 74). Among authors, Richards, C D had the most publications (n = 34) and co-citations (n = 18990), indicating his significant contributions. Keyword analysis revealed that OSM research primarily related to disease such as tumor, inflammatory bowel disease (IBD), myocardial infarction (MI), chronic rhinosinusitis (CRS) and atopic dermatitis (AD). Research on AD, IBD and CRS has remained active to the present.
conclusionThis bibliometric analysis delineates the primary contributing countries, authors, institutions, and journals in OSM research. The identified hotspots and frontiers underscore the broad physiological roles of OSM. This study provides an objective reference for future scientific research on OSM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.